HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

January 31, 2026

Conditions

Hepatocellular Carcinoma With PVTT

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg, iv, d3, q3w

DRUG

Lenvatinib

Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd

Trial Locations (1)

Eastern Hepatobiliary Surgery Hospital, Yangpu

All Listed Sponsors

lead

Li Xiao Wei

OTHER